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Summary
The complement system augments the humoral immune response to low concentrations ofantigen .
This effect may be partly mediated by complement receptors on the surface of B lymphocytes
that bind immunogenic complexes bearing fragments of C3 and C4. We have shown by
immunoprecipitation analysis that the two complement receptors expressed by B lymphocytes,
complement receptor 1 (CR1) and CR2, form a detergent-sensitive complex on the surface of
tonsillar B lymphocytes and onK562 erythroleukemia cells that were co-transfected withcDNAs
encoding CRI and CR2 . The CR1/CR2 complex is distinct from the CR2/CD19 complex
andmay assistB cell activation by efficiently capturing Cab-containing immunogens and maintaining
such immunogens on the B cell after CR1 and factor 1-mediated cleavage to iC3b and C3dg.
The complement activatingimmunogen may then trigger signal transduction by the CRl/CR2
complex, the CR2/CD19 complex, or membrane immunoglobulin .
S
tudies in animals and humans have shown that inherited
or experimentally induced deficiencies in components of
the classical pathway ofcomplement activation are associated
with a diminished humoral immune response toT -dependent
and -independent antigens (1-6) . This phenomenon may be
based on the ability ofC3 fragments deposited on a classical
pathway activating immune complex to modulate B cell re-
sponses to antigen . B cells have two integral membrane pro-
teins that interact with fragments ofC3 : complement receptor
type 1 (CRI, CD35), a 220-kD protein that binds the pri-
mary activation fragment ofC3, C3b, and serves as a cofactor
for its cleavage toiC3b and C3dg, and complement receptor
type 2 (CR2, CD21), a 145-kD protein that binds the iC3b
and C3dg fragments (7, 8) .
CRI and CR2 have been shown individually to elicit sev-
eral B cell functions, such as enhancement by ligated CRI
of the differentiation into antibody-secreting cells (9, 10), and
augmented cellular proliferation by ligated CR2 in combi-
nation with PMA (11), T cell derived factors (12), and anti-
IgM (13), respectively . Two studies have compared the two
receptors for their participation in defined B cell responses
and have suggested that CR2may have functions not shared
by CRl. In the first study, crosslinking of CR2, but not
CRl, to membrane IgM on B cells was shown to increase
synergistically the intracellular [Caz+1 (14), and, in the
second, administration to mice ofa mAb reactive with both
CRl and CR2 wasmore effective in suppressing theimmune
response to sheep erythrocytes than was an antibody specific
for CRI (15) .
A molecular basis for signal transduction by CR2, and pos-
sibly for its unique biological function relative to CR1, has
been suggested recently to be its association with a mem-
brane protein complex on the B cell that contains CD19 and
several other unidentified components (16) . However, the as-
sociation of CRl with CD19 could not be assessed in this
study because the B lymphoblastoid cell line in which the
CR2/CD19 complex was demonstrated did not express CRl .
We have now determined the molecular complexes formed
by CRl, CR2, and CD19 on normal tonsillar B lympho-
cytes that express all three proteins and find that CR1 forms
a complex with CR2 and that these CR1/CR2 complexes,
in contrast to CR2 alone, do not associate with CD19 .
Materials and Methods
Monoclonal Antibodies, Cells, and Immunoprecipitations.
￿
The anti-
CR1 mAbs YZI (17) and 3139 (18), the anti-CR2 mAbs HB5 (19,
20) andOKB7 (Ortho Diagnostic Systems Inc., Westwood, MA),
the anti-CD19mAb HD37 (Dako Corp ., Santa Barbara, CA), and
W6/32 anti-HLA class I (American Type Culture Collection
[ATCC], Rockville, MD) were used . Control antibodies for non-
specific immunoprecipitations were RPC5.4 IgG2a (ATCC) and
MOPC21 IgGI (Cappel Laboratories, Malvern, PA) . Tonsillar B
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cells were grown inRPMI supplemented with10% FCS, 100U/ml
penicillin, 100 Wg/ml streptomycin, and2MM . L-glutamine. Cells
were radiolabeled with 1251 (21), lysed using either NP40 or
digitonin, immunoprecipitated, and analyzed by polyacrylamide gel
electrophoresis in the presence ofSDS (SDS-PAGE) under reducing
conditions (16) . Rabbit gammaglobulin (Sigma Chemical Co ., St.
Louis, MO)bound to CNBr-activated Sepharose (Sigma Chemical
Co.) was used to preclear the lysates, and rabbit anti-mouse Ig
(Cappel Laboratories) bound to CNBr-activated Sepharosewas used
for specific immunoprecipitations.
Transfection ofK562 Cells withcDNA Constructs.
￿
pLNCX.CR2
encodes neomycin resistance and CR2 under transcriptional con-
trol of a Maloney murine leukemia virus (MLV) long terminal
repeat (LTR) andtheCMVimmediate early promoter, respectively.
It was created by digestion ofpLNCX (22) and pBS.CR2 .1 (23)
with Hind III and Not I, respectively, and treatment of both
plasmids with Klenow fragment followed by Cla I digestion and
ligation . p141.CD19 confers hygromycin resistance controlled by
the HSV tk gene promoter and encodesCD19 driven by theMLV
LTR . It was created by digestion of p141 (24) and pZip.neo.
SV(CD19) (16) with Hind III and ligation ofthe appropriate frag-
ments . piABCD encodes thecDNA forCRl under control of the
CMV immediate earlypromoter (25) . K562 cells were transfected
and selected as described (16) . K562 cells were cotransfected with
the expression plasmids for CR2 and CRl, pLNCX.CR2 and pi-
ABCD, and selected with neomycin to generateCRl`CR2`K562
cells, or cotransfected with piABCD and the CD19-expressing
plasmid, p141.CD19, and selected with hygromycin to generate
CRl' CD19 *K562 cells, or triply-transfected with piABCD,
pLNCX.CR2, and p141.CD19 and selected with both neomycin
andhygromycin to generate CRl*CR2*CD19 ` K562 cells . Cells
expressing high levels of the recombinant proteins were obtained
by immunofluorescent staining followed by sorting on a FACStar-
Plus flow cytometer(BectonDickinson and Co ., Sunnyvale, CA) .
1084 CRl/CR2 Complex on B Lymphocytes
Figure 1.
￿
Autoradiograph of SDS-polyacrylamide gel ofimmunoprecipi-
tates obtained from digitonin lysates of 1251 surface-labeled tonsillarBlym-
phocytes with HD37 anti-CD19 (lane 1), YZl anti-CRI (lane 2), HB5
anti-CR2 (lane 3), and W6/32 anti-HLA (lane 4), respectively. The ar-
rowheads on the left side and on the right side indicate the positions of
specifically immunoprecipitated proteins in lanes 1-3, and lane 4, respec-
tively.
Results
Association ofCRl with CR2 but not CD19 on B Lympho-
cytes.
￿
To studymolecular complexeson B lymphocytesthat
Figure 2.
￿
Autoradiographs of SDS-polyacrylamide gels of immuno-
precipitates obtained from digitonin lysates (A) and NP401ysates (B) of
1251-labeled tonsillar B lymphocytes with W6/32 anti-HLA (lane 1), HB5
anti-CR2 (lane 2), OKB7 anti-CR2 (lane 3),YZl anti-CRI (lane 4), and
3D9 anti-CRI (lane 5), respectively. (C) Autoradiographs of SDS-poly-
acrylamide gels ofthe membrane proteins reimmunoprecipitated from the
NP40/SDS eluate of the complexes obtained from digitonin lysates of
1251-labeled tonsillarB lymphocytes by anti-CR2 (lanes 1 and 2), and anti-
CRl (lanes 3 and 4) . The immunoprecipitates prepared from digitonin
lysates were incubated with 2% NP40/0.2% SDS for 30 min, and the
eluates from the anti-CR2 and anti-CRI precipitates were immunopre-
cipitated with control MOPC21 IgGI (lane 1) andYZI anti-CRI (lane
2), andcontrolRPC5.4 IgG2a (lane3) andHB5 anti-CR2 (lane4), respec-
tively. The arrowheads indicate the positions of specifically immunopre-
cipitated proteins.contain complement receptors, digitonin lysates of "'I-la-
beled tonsillarB cells were immunoprecipitated with mono-
clonal anti-CR1, anti-CR2, and anti-CD19, respectively (Fig.
1) . Analysis bySDS-PAGE ofthe immunoprecipitate obtained
with anti-CD19 revealed the components oftheCR2/CD19
complex : CR2 at 145 kD, CD19 at 95kD and the unidentified
protein at 20 kD, p20 (16) (lane 1) . Monoclonal anti-CR1
immunoprecipitated CR1 at 220 kD and another protein at
145 kD having the same mobility as CR2 (lane 2) . The im-
munoprecipitate obtained with anti-CR2 revealed all the com-
ponents seen with anti-CD19 and anti-CR1 : the CR2/CD19
complex and a protein at 220 kD having the same mobility
as CR1(lane 3) . The protein at 130 kD coprecipitating with
CR2 has been noted previously and has not been identified
(16) . The control immunoprecipitate ofclass I HLA revealed
the heavy and light chains of class I at 40 kD and 12 kD,
respectively, but did not contain any of the specific bands
seen in lanes 1, 2, and 3 (lane 4) .
To determine whether the complex between the 220-kD
and 145-kD proteins was dependent on the type ofdetergent
and the particular monoclonal anti-receptor antibodies used,
digitonin and NP40 lysates were prepared from 1251-surface
labeled tonsillar B cells, and precipitates were obtained with
four different mAbs. Immunoprecipitates from digitonin ly-
sates again revealed the coprecipitation of a 220-kD protein
with either of two anti-CR2 mAbs that bind to distinct epi-
topes, HB5 and OKB7 (23), and the coprecipitation of a 145-
kD protein with either of two anti-CRI mAbs that bind
to distinct epitopes, YZl and 3D9 (our unpublished obser-
vation) (Fig. 2 A) . In contrast, immunoprecipitates obtained
with these mAbs from NP40 lysates revealed only proteins
for which the mAbs were specific (Fig. 2 B) .
The differential sensitivity o£ the complexes to detergents
permitted the direct identification ofthe coprecipitating pro-
teins as CR1 and CR2 . Immunoprecipitates were prepared
from digitonin lysates with anti-CR1 and anti-CR2, respec-
tively, and treated with NP40 to release any components sen-
sitive to this detergent . Reprecipitation from the NP40 eluates
demonstrated that CR1 was specifically recovered from the
anti-CR2 immunoprecipitate (Fig. 2 C, lane 2), and that CR2
was recovered from the anti-CR1 immunoprecipitate (Fig .
2 C, lane 4) .
Reconstitution ofthe CRI/CR2 Complex in TransfectedK562
Erythroleukemia Cells. In a previous study, the CR2/CD19
complex had been reconstituted in K562 cells by stably ex-
pressing recombinant forms of these proteins (16) . Having
determined that an additional complex ofCR1 and CR2 is
present on normalB lymphocytes, K562 cells, which do not
express CR1 constitutively, were transfected with plasmids
containingcDNAs encoding CR1 and CR2 to assess the for-
mation of the CRI/CR2 complex in this cell type . Cell lines
expressing both receptors were analyzed by fluorescent flow
cytometry (Fig . 3 A), and labeled with 1251 . Immunoprecipi-
tates obtained with anti-CR1 and anti-CR2, respectively, from
digitonin lysates of the CR1+CR2+K562 cells demon-
strated the presence of the coprecipitating receptor in each
instance (Fig. 3 B), indicating the formation of theCRI/CR2
complex. In these experiments, a specific band at 190 kD was
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also observed which has not been identified, but may repre-
sent a variably glycosylated form of CRl .
To determine whether CR1 could associate with CD19
in the absence of CR2, K562 cells were doubly transfected
with cDNAs encoding CR1 andCD19 . Cells expressing both
proteins (Fig . 4A) were labeled with 1251, lysed in digitonin
and subjected to immunoprecipitation with anti-CRI and
anti-CD19, respectively (Fig . 4 B) . Only the protein primarily
reacting with the mAb was detected by SDS-PAGE, indi-
cating that in the K562 cell, as had been observed with B
Figure 3.
￿
(A) Flow cytometric analysis ofK562 cells stably expressing
recombinantCR1 andCR2 that had been indirectly stained with control
antibody (solidline), YZ1 anti-CR1(tightly spaceddotted line), or HB5 anti-
CR2 (loosely spaced dotted line) followed by fluorescein-conjugated goat
anti-mouse Ig . (B) Autoradiograph of SDS-polyacrylamide gel of im-
munoprecipitates obtained from digitonin lysates of 12SI-labeled K562 cells
expressing recombinantCRI andCR2 with YZ1 anti-CRI (lane 1), con-
trolMOPC21 IgG1(lane 2), HB5 anti-CR2 (lane 3), and control RPC5.4
IgG2a (lane 4), respectively. The arrowheads indicate the positions of
specifically immunoprecipitated proteins.LOG FLUORESCENCEMIENSMY
Figure 4 .
￿
(A) Flow cytometric analysis ofK562 cells stably expressing
recombinant CR1 and CD19 that had been indirectly stained with con-
trol antibody (solid line), YZI anti-CRI (loosely spaced dotted line), and HD37
anti-CD19 (tightly spaceddotted line) followed by fluorescein-conjugated goat
anti-mouse Ig. (B) Autoradiograph of SDS-polyacrylamide gel of im-
munoprecipitates obtained from digitonin lysates of 1251-labeled K562 cells
expressing recombinant CRI and CD19 with YZ1 anti-CRI (lane 1), con-
trol MOPC21 IgGI (lane 2), andHD37 anti-CD19 (lane3), respectively.
The arrowheads indicate the positions ofspecifically immunoprecipitated
proteins .
cells, CR1 and CD19 do not form a complex detectable by
this assay.
To reconstitute the entire ensemble of complement receptor-
containing complexes found on B lymphocytes, K562 cells
were triply transfected with cDNAs encoding CRl, CR2,
and CD19 . Analysis of the triple transfectants by flow cytom-
etry showed expression ofall three molecules (Fig . 5 A), and
immunoprecipitation from digitonin lysates ofsurface-labeled
cells indicated that only theCR1/CR2 complex was obtained
with anti-CR1(Fig. 5 B, lane 1), only the CR2/CD19 com-
plex with anti-CD19 (lane 3), and both complexes with anti-
CR2 (lane S) . Thus, elements unique toB lymphocytes, other
than the three transfected membrane proteins, are not required
for the assembly ofthe complement receptor-containing com-
plexes.
Discussion
A molecular complex containing CR1 and CR2 resides
on the surface of B lymphocytes. The CR1/CR2 complex
is immunoprecipitated from digitonin, but not NP40, deter-
gent lysates by several mAbs directed against either CR1 or
CR2 (Fig. 2,A and B), indicating that the coprecipitation
1086 CR1/CR2 Complex on B Lymphocytes
is not due to antigenic crossreactivity between these homol-
ogous proteins. The coprecipitating proteins were identified
asCR1 or CR2 by eluting the immunoprecipitates obtained
from digitonin lysates with NP40 and immunoprecipitating
the associated receptor from the NP40 eluate with the rele-
vant mAb (Fig. 2 C) . In some experiments, most of the CR1
appeared to coprecipitate with CR2, suggesting that little
or noCRl was in an uncomplexed state (Fig. 1) . Expressing
recombinant CR1 and CR2 in K562 erythroleukemia cells
reconstituted theCR1/CR2 complex (Fig. 3), indicating that
no other lymphoid-specific components were necessary and
suggesting that CR1 and CR2 directly interact .
The CR1/CR2 complex is distinct from the CR2/CD19
complex, as is schematically depicted in Fig. 6 . Immunoprecipi-
tates of CR1 from B lymphocytes (Fig. 1) or triply trans-
fected K562 cells (Fig. 5) coprecipitated CR2 but not CD19,
and, conversely, immunoprecipitates ofCD19 from both cell
types coprecipitated CR2 but not CR1 . Furthermore, the
lack of association between CR1 and CD19 is not caused
by competition by CR2 because a CR1/CD19 complex also
could not be demonstrated on K562 cells expressing these
recombinant proteins in the absence of CR2 (Fig . 4) . The
mutual exclusivity ofCR2 for either CR1 orCD19 may beFigure 5 .
￿
(A) Flow cytometric analysis of K562 cells stably expressing recombinant CRl, CR2 and CD19 that had been indirectly stained with
control antibody (solid line), YZl anti-CR1(tightly spaced dotted line), HB5 anti-CR2 (looselyspaceddotted line), andHD37 anti-CD19 (dashed line) followed
by fluorescein-conjugated goat anti-mouse Ig. (B) Autoradiograph of SDS-polyacrylamide gel of immunoprecipitates obtained from digitonin lysates
of 12 5I-labeled K562 cells expressing recombinant CRl, CR2, and CD19 with YZl anti-CR1 (lane 1), control MOPC21 IgGI (lane 2), HD37 anti-
CD19 (lane 3), control RPC5.4 IgG2a (lane 4), andHB5 anti-CR2 (lane S), respectively. The arrowheads indicate the positions of specifically immuno-
precipitated proteins .
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the result of a common site on CR2 interacting with both
CR1 and CD19, a circumstance that would prevent the for-
mation ofa multimolecular complex containingCR1, CR2,
andCD19. The apparently greateramount ofCR2 obtained
by immunoprecipitating with anti-CR2 than with anti-CR1
and anti-CD19 taken together (Fig . 1), suggests that uncom-
plexed CR2 is present on the membrane, perhaps for the pur-
pose of enhancing multivalent interactions with ligands at
the CRl/CR2 andCR2/CD19 complexes, or for preventing
the cross-ligation of the CRl/CR2 and CR2/CD19 com-
plexes .
The finding of two distinct complexes that contain com-
plement receptors indicates that an intricate set of interac-
tions may occur between B lymphocytes and immunogenic
activators ofcomplement that bear fragments ofC3 . An ini-
Figure 6.
￿
Molecular interactions involving complement receptors on
B lymphocytes. CRl andCR2 are comprised ofrepetitive structural ele-
ments termed short consensus repeats (SCRs) (7), and CD19 is a member
of the Ig superfamily containing two extracellular Ig domains (32, 33)
and associates with p20 (16) . The Cab binding sites on CRl are indicated
by shaded SCRs (25), and the iC3b/C3dg binding site onCR2 by closed
SCRs (23) ; a ligand for CD19 has not been identified . The close apposi-
tion of the Cab binding sites in CR1 and the iC3b/C3dg binding site
inCR2 may facilitate the intracomplex transfer ofC3 ligands fromCR1
to CR2 after proteolysis by factor I . The mutually exclusive interaction
between CR2 and eitherCR1 or CD19 provides a potential mechanism
for theB cell todiscriminate between activators ofthe alternative and clas-
sical pathways . Free CR2 may stabilize binding of ligand to either the
CRI/CR2 or CR2/CD19 complexes.tial function of the CR1/CR2 complex may be the capture
of complement activators in which C3 is principally in the
Cab form, as would occur with alternative pathway activators
(26) . The Cab would be converted rapidly to iC3b andC3dg
through the concerted actions ofCR1 and factor I (27), and
the complement activator would transfer preferentially to the
associated CR2 rather than to free CR2 or the CR2/CD19
complexes. The association of CR1 with CR2 may also
diminish the likelihood that theimmunogen would dissociate
from the cell following proteolytic processing of Cab . This
consideration may be important for immunogen retention
on follicular dendritic cells that express both CR1 andCR2
(28), and relate to the proposal that murine CR1 is an ex-
tended form ofCR2, possibly having CR2 ligand binding
capability (29-31) .
LigatedCRI/CR2 complex on the B cell may have signal
transducing functions, perhaps in relation to cellular differ-
entiation into an antibody-secreting state (9, 10), that are
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